Thomas P. Mathers

Tom Mathers is the co-founder of Allievex Corp. and serves as its President and CEO, and director. He is also a partner at Pappas Capital, a dedicated life science venture capital firm focused exclusively on investing in the life sciences sector, where Tom focuses primarily on company formation.

Prior to Pappas Capital and Allievex, Tom was the President and CEO of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), which focused on the development of lasmiditan for the acute treatment of migraine headaches. Eli Lilly & Company acquired CoLucid in March 2017 in an all-cash transaction worth nearly $1 billion. Prior to CoLucid, Tom was President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery, Inc.; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at Genzyme Corporation.

Tom currently serves as a Trustee of Butler University, as a director for LifeSci Acquisition Corporation II (NASDAQ: LSAQ), a healthcare special purpose acquisition corporation, and as a business advisor to the Progeria Research Foundation. He served for nine years on the board of directors for the Biotechnology Industry Organization, where he was active in the policy areas of capital formation, bioethics, intellectual property, and regulatory policy. He also served as a board observer for 4D Molecular Therapeutics, Inc. From 1988 to 1991, Tom served as a captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War.